Key Highlights
- Veeda invests in Mango Sciences to integrate its AI platform Querent™ and boost oncology trial diversity, speed, and precision across Europe and India.
- Partnership includes LLM and generative AI capabilities to optimize patient recruitment, real-world evidence, and operational performance.
- Veeda positions itself as one of the few oncology-focused CROs globally with proprietary AI infrastructure for diverse clinical development.
AI-Driven Precision in Global Trial Recruitment
Veeda Lifesciences, a global CRO, has announced a strategic investment in Boston-based Mango Sciences to adopt the AI-powered Querent™ platform for enhancing clinical trial efficiency and patient diversity. The collaboration aims to accelerate oncology drug development by using AI to automate and refine patient identification—especially across non-Caucasian cohorts in India and Europe. This step directly responds to growing regulatory and sponsor demand for inclusive, data-rich trials.
Next-Gen Trial Efficiency Through Generative AI
Mango Sciences’ AI stack, including the integration of Large Language Models (LLMs) and generative AI, will enable advanced real-world data analysis, personalized trial matching, and improved study design. For Veeda, this translates into faster site activation, reduced screening failures, and lower operational costs. The Querent™ platform will be deployed across Veeda’s global network, embedding AI into every stage of the trial lifecycle—from protocol design to post-market analytics.
Exclusive Access to Oncology Cohorts in India and Europe
As part of this digital transformation, Veeda gains exclusive access to oncology patient pools across India and Europe, bolstered by its prior acquisition of Health Data Specialists. The combined datasets will inform Mango’s AI models and strengthen Veeda’s capabilities in biomarker-driven, oncology-focused studies—giving pharmaceutical sponsors a competitive edge in reaching globally representative patient populations.
Building the AI-Powered CRO of the Future
This partnership marks a strategic milestone in Veeda’s mission to evolve from a traditional CRO into a tech-forward, AI-enabled development partner. “This alliance positions Veeda among the few CROs globally equipped with proprietary AI for oncology trials,” said Dr. Mahesh Bhalgat, Group CEO & Managing Director. “It directly supports our vision to be at the forefront of diversity-driven, digital-first clinical development.”
About Veeda Lifesciences
Veeda Lifesciences is a global contract research organization (CRO) offering a full suite of services across the drug development spectrum. With specialized capabilities in oncology and a strong presence in Europe and Asia, Veeda supports biopharma innovators with advanced infrastructure, a global site network, and a growing portfolio of AI-powered technologies to accelerate clinical programs efficiently and ethically.
About Mango Sciences
Mango Sciences is a healthcare AI and data company focused on improving global access to precision medicine. Its flagship platform, Querent™, applies AI and machine learning—including LLMs and generative models—to optimize patient recruitment, real-world evidence generation, and therapeutic targeting. Based in Boston and operating globally, Mango Sciences partners with CROs, life sciences firms, and payers to bring AI innovation to underserved clinical ecosystems.
By
